Published: Jun, 2018

The asthma and COPD drugs market in US and China is expected to show a consolidated competitive landscape. In 2015, the leading players within the US and China asthma and COPD drugs Market accounted for 64% of the total Market, according to a recent research report by transparency market research TMR. The names of the leading players within the US and China asthma and COPD drugs market are: Merck & Co. Inc., Astrazeneca plc, Novartis AG, GlaxoSmithKline plc, and Boehringer Ingelheim.

According to the TMR report, the US and China asthma and COPD drugs market will be worth US$18.7 bn by 2024. On the basis of different types or classes of drugs come on the market is segmented into anti-inflammatory drugs, combination drugs, bronchodilators, and monoclonal antibodies. Among these, it is the combination drug segment which is witnessing highest growth. The segment accounted for 54% of the total US market in 2015. The combination drug segment is expected to continue to lead throughout the focus period on account of positive recommendations from organizations such as Global initiative for asthma and Global Initiative for chronic obstructive lung disease, which state that blends the dates are more secure course of treating asthma and COPD.

us china asthma copd drugs market

US Accounted for 81% of Market in 2016

On the basis of geography, among the US and China, it is the US which is dominating in the asthma and COPD drugs Market on account of High awareness level among the people regarding the availability of drugs and treatment options. Regular product launches and continues Investments by leading players in the research and development sector will also help the market to grow in the US. In 2016, the US accounted for a whopping 81% of the total market.

Growing Air Pollution Behind Growth in China Asthma and COPD Drugs Market

China on the other hand accounts for the relatively small share in the asthma and COPD drugs Market, but is expected to present liquid growth opportunities for Market players in the coming years. China is expected to exhibit at 10% in the asthma COPD drugs Market. The factors associated with the increasing number of asthma patients, Rising air pollution, and vast unmet medical needs of the patient population. The increasing number of smokers is also an important factor contributed to the growth of the market in China.

Rising Number of Deaths due to COPD and Asthma Behind High Demand for Treatment

According to the lead author of this report, asthma and COPD are two disorders which are affecting a large number of population today and is behind the growth of the US and China asthma and COPD drugs market. These two disorders are increasingly becoming a factor for increased number of deaths and therefore effective treatment is highly in demand. The FDA endorsements for novel treatment options is expected to contribute to the growth of the US and China asthma and COPD drugs market. So the other factors helping the market to grow is the growing geriatric population, lifestyle changes, increasing number of smokers, increase in pollution, and rising industrialization.

The data and information presented in this review are based on a TMR report titled as “Asthma and COPD Drugs Market (Drug Class - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs; Indication - Asthma and COPD) - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024”

U.S. and China Asthma and COPD Drugs Market, by Drug Class

  • Bronchodilators 
    • Short Acting Beta-2 Agonists
    • Long Acting Beta-2 Agonists
    • Anti-cholinergic Agents 
  • Anti-inflammatory Drugs
    • Oral and Inhaled Corticosteroids
    • Anti-leukotrienes
    • Phosphodiesterase Type-4 Inhibitors
    • Others 
  • Monoclonal Antibodies
  • Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

  • Asthma
  • COPD

About Us

“Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com 
Website: https://www.transparencymarketresearch.com 

.